FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387332125> ?p ?o ?g. }

• W4387332125 abstract "Abstract In spite of significant strides in the realm of cancer biology and therapeutic interventions, the clinical prognosis for patients afflicted with glioblastoma (GBM) remains distressingly dismal. The tumor immune microenvironment (TIME), a crucial player in the progression, treatment response, and prognostic trajectory of glioma, warrants thorough exploration. Within this intricate microcosm, the immunosuppressive checkpoint protein PD‐L1 and tumor‐infiltrating lymphocytes (TILs) emerge as pivotal constituents, underscoring their potential role in deciphering glioma biology and informing treatment strategies. However, prognostic models based on the association between PD‐L1 expression and TIL infiltration in the tumor immune microenvironment have not been established. The aim of this study was to explore TIME genes associated with PD‐L1 expression and TIL invasion and to construct a risk score for predicting the overall survival (OS) of GBM patients based on these genes. The samples were separately classified according to the PD‐L1 expression level and TIL score and TIME‐related genes were identified using differential expression and weighted gene co‐expression network analysis. The DEGs were subjected to least absolute contraction and selection operator (LASSO) ‐Cox regression to construct TIME associated risk score (TIMErisk). A TIMErisk was developed based on STEAP3 and CXCL13 genes. The STLEAP3 was demonstrated to be involved in glioma progression. The results showed that the patients in the high TIMErisk group had poor OS compared with subjects in the low TIMErisk group. The biological phenotypes associated with TIMErisk were analyzed in terms of functional enrichment, tumor immune profile, and tumor mutation profile. The results on tumor immune dysfunction and exclusion dysfunction (TIDE) score and immune surface score (IPS) showed that GBM patients with different TIME risks had different responses to immunotherapy. Tumor purity analysis indicated that PD‐L1 and TIL scores were positively correlated with TIMErisk score and negatively correlated with tumor purity. These results show that the TIMErisk‐based prognostic model had high predictive value for the prognosis and immune characteristics of GBM patients. Immunohistochemical staining images of patients in the high and low TIMErisk groups were analyzed, showing that the degree of immune cell infiltration was higher in the high TIMErisk group relative to the low TIMErisk group. The present study provides a basis for understanding glioma tumor microenvironment and a foundation for conducting comprehensive immunogenomic analysis." @default.
• W4387332125 created "2023-10-05" @default.
• W4387332125 creator A5004586541 @default.
• W4387332125 creator A5045893552 @default.
• W4387332125 creator A5065215852 @default.
• W4387332125 creator A5070538147 @default.
• W4387332125 creator A5071915668 @default.
• W4387332125 date "2023-10-04" @default.
• W4387332125 modified "2023-10-06" @default.
• W4387332125 title "The levels of immunosuppressive checkpoint protein <scp>PD‐L1</scp> and tumor‐infiltrating lymphocytes were integrated to reveal the glioma tumor microenvironment" @default.
• W4387332125 cites W1625203433 @default.
• W4387332125 cites W1966116114 @default.
• W4387332125 cites W1966327575 @default.
• W4387332125 cites W1985844340 @default.
• W4387332125 cites W1990337776 @default.
• W4387332125 cites W2022976025 @default.
• W4387332125 cites W2028433016 @default.
• W4387332125 cites W2061228541 @default.
• W4387332125 cites W2068229930 @default.
• W4387332125 cites W2068335734 @default.
• W4387332125 cites W2075294566 @default.
• W4387332125 cites W2089828715 @default.
• W4387332125 cites W2096287682 @default.
• W4387332125 cites W2140916658 @default.
• W4387332125 cites W2158681922 @default.
• W4387332125 cites W2160382843 @default.
• W4387332125 cites W2163309283 @default.
• W4387332125 cites W2295059886 @default.
• W4387332125 cites W2299181842 @default.
• W4387332125 cites W2329659234 @default.
• W4387332125 cites W2366536035 @default.
• W4387332125 cites W2515648638 @default.
• W4387332125 cites W2612114921 @default.
• W4387332125 cites W2739998491 @default.
• W4387332125 cites W2897222331 @default.
• W4387332125 cites W2904210127 @default.
• W4387332125 cites W2923042525 @default.
• W4387332125 cites W2940666965 @default.
• W4387332125 cites W2959190003 @default.
• W4387332125 cites W2972783054 @default.
• W4387332125 cites W2976744492 @default.
• W4387332125 cites W3011350845 @default.
• W4387332125 cites W3012408003 @default.
• W4387332125 cites W3024542302 @default.
• W4387332125 cites W3049387264 @default.
• W4387332125 cites W3092298447 @default.
• W4387332125 cites W3093363809 @default.
• W4387332125 cites W3185482622 @default.
• W4387332125 cites W3190574243 @default.
• W4387332125 cites W4210449656 @default.
• W4387332125 cites W4220668192 @default.
• W4387332125 doi "https://doi.org/10.1002/tox.23979" @default.
• W4387332125 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37792606" @default.
• W4387332125 hasPublicationYear "2023" @default.
• W4387332125 type Work @default.
• W4387332125 citedByCount "0" @default.
• W4387332125 crossrefType "journal-article" @default.
• W4387332125 hasAuthorship W4387332125A5004586541 @default.
• W4387332125 hasAuthorship W4387332125A5045893552 @default.
• W4387332125 hasAuthorship W4387332125A5065215852 @default.
• W4387332125 hasAuthorship W4387332125A5070538147 @default.
• W4387332125 hasAuthorship W4387332125A5071915668 @default.
• W4387332125 hasBestOaLocation W43873321251 @default.
• W4387332125 hasConcept C104317684 @default.
• W4387332125 hasConcept C126322002 @default.
• W4387332125 hasConcept C143998085 @default.
• W4387332125 hasConcept C167672396 @default.
• W4387332125 hasConcept C203014093 @default.
• W4387332125 hasConcept C2776107976 @default.
• W4387332125 hasConcept C2777701055 @default.
• W4387332125 hasConcept C2777863537 @default.
• W4387332125 hasConcept C2778227246 @default.
• W4387332125 hasConcept C2778326572 @default.
• W4387332125 hasConcept C2779256057 @default.
• W4387332125 hasConcept C2780851360 @default.
• W4387332125 hasConcept C502942594 @default.
• W4387332125 hasConcept C50382708 @default.
• W4387332125 hasConcept C54355233 @default.
• W4387332125 hasConcept C71924100 @default.
• W4387332125 hasConcept C86803240 @default.
• W4387332125 hasConcept C8891405 @default.
• W4387332125 hasConceptScore W4387332125C104317684 @default.
• W4387332125 hasConceptScore W4387332125C126322002 @default.
• W4387332125 hasConceptScore W4387332125C143998085 @default.
• W4387332125 hasConceptScore W4387332125C167672396 @default.
• W4387332125 hasConceptScore W4387332125C203014093 @default.
• W4387332125 hasConceptScore W4387332125C2776107976 @default.
• W4387332125 hasConceptScore W4387332125C2777701055 @default.
• W4387332125 hasConceptScore W4387332125C2777863537 @default.
• W4387332125 hasConceptScore W4387332125C2778227246 @default.
• W4387332125 hasConceptScore W4387332125C2778326572 @default.
• W4387332125 hasConceptScore W4387332125C2779256057 @default.
• W4387332125 hasConceptScore W4387332125C2780851360 @default.
• W4387332125 hasConceptScore W4387332125C502942594 @default.
• W4387332125 hasConceptScore W4387332125C50382708 @default.
• W4387332125 hasConceptScore W4387332125C54355233 @default.
• W4387332125 hasConceptScore W4387332125C71924100 @default.
• W4387332125 hasConceptScore W4387332125C86803240 @default.
• W4387332125 hasConceptScore W4387332125C8891405 @default.
• W4387332125 hasLocation W43873321251 @default.

• next